Long-Term Survival (>25 Years) of Deceased Donor Kidney Transplant Recipients: a Single-Center Experience

INTRODUCTION: The aim of this preliminary work is to analyze the clinical features of 52 patients with a functional transplanted kidney for >25 years (all first transplant and all deceased donor recipients) and to compare with a similar though more complete study from Hôpital Necker-Paris 2012. METHODS: The mean graft survival at 25 years is 12.7% and at 30 years is 10%. The actual mean serum creatinine concentration is 1.3 mg/L. We analyzed recipient age (mean, 35.9 years) and gender (29 men and 23 women). Donor age was 26.7 ± 10.3 years. Seven patients (13.4%) were transplanted with 1 HLA mismatch, 42.3% with 2 mismatches, and 44.2% with 3 mismatches. Mean cold ischemia time was 15.45 ± 7.7 hours. Of the recipients, 76% had immediate graft function; 38% experienced 1 acute rejection episode and 4 patients had 2 rejection crises. The initial immunosuppressive regimen was azathioprine (AZA) + prednisolone (Pred) in 14 patients, cyclosporin (CSA) + Pred in 13 patients, and CSA + AZA + Pred in 25 patients. Of these patients, 19% maintained their initial regimen, and 54% (28 patients) were very stable on a mixed CSA regimen for >25 years. RESULTS: We present the major complications (diabetes, neoplasia, and hepatitis C virus positivity). CONCLUSION: Our results in deceased donor kidney recipients for >25 years are similar to the mixed population (deceased donors and living donors) presented by the Necker group, although 54% of our patients remain on CSA immunosuppression, contradicting the idea that its use is not compatible with good long-term kidney function in transplant recipients.

Avaliação de genótipos de girassol em Mato Grosso, na safrinha de 2014.

RESUMO: Objetivou-se avaliar o desempenho agronômico de genótipos de girassol, em ensaio da Rede de Ensaios de Avaliação de Genótipos de Girassol, na safrinha de 2014, visando à indicação para cultivo no Estado de Mato Grosso. O experimento foi conduzido na área experimental do Instituto Federal de Mato Grosso (IFMT), campus de São Vicente - MT, na safrinha de 2014, empregando-se delineamento em blocos ao acaso, com quatro repetições. Foram efetuadas avaliações de altura de planta, rendimento de aquênios, teor de óleo e rendimento de óleo. Os resultados foram submetidos à análise de variância e as médias foram comparadas pelo teste de Duncan ao nível de 5% de significância. Os genótipos GNZ NEON, SYN 045, AGUARÁ 06, M734, MG 360 e MG 305 foram superiores na avaliação de rendimento de aquênios. Em teor de óleo, os genótipos MG 360, MG 305, HLA 2012, SYN 3950HO, PARAÍSO 20 e AGUARÁ 04 se destacaram. O intenso ataque de pássaros prejudicou o desempenho dos genótipos de girassol. ABSTRACT: This work aimed to evaluate the agronomic performance of the sunflower genotypes under testing by the Network of Evaluative Experiments with Sunflower Genotypes, on off-season of 2014, proposing an indication for cultivation in the state of Mato Grosso, Brazil. Experiment was conducted in the Federal Institute of Mato Grosso, campus of São Vicente - MT, using randomized complete block design, with four replications. Measurements were made, evaluating plant height, achene yield, oil content and oil yield. The results were submitted to analysis of variance and compared using the Duncan test at 5% of significance level. Genotypes GNZ NEON, SYN 045, AGUARÁ 06, M734, MG 360 and MG 305 were higher in achenes yield evaluation. Regarding oil content, the genotypes MG 360, MG 305, HLA 2012, SYN 3950HO, PARAISO 20 and AGUARÁ 04 were best. The intense attack of birds affected performance of sunflower genotypes.

Associação dos antígenos leucocitários humanos com a ausência de resposta humoral à vacina da hepatite B em pacientes renais crônicos hemodialisados

A vacinação com antígeno de superfície do vírus da hepatite B não tem eficácia satisfatória em pacientes hemodialisados. O objetivo do estudo foi investigar uma possível associação entre antígenos leucocitários humanos e a baixa capacidade de produção de anticorpos protetores (anti-HbS) contra o antígeno de superfície do vírus da hepatite B em pacientes renais crônicos de programa de hemodiálise. Os antígenos HLA DR e DQ foram determinados em 76 pacientes hemodialisados por meio da técnica clássica de microlinfocitotoxicidade. Os resultados demonstraram que 34,2% dos pacientes eram não-respondedores à vacina VHB. As especificidades HLA mais freqüentes foram: HLA-DR3, DR7 e DQ2, com associação significante para a especificidade HLA-DR3 (p=0,0025; OR 5,1; IC95% 1,36-19,10). Estes dados sugerem a associação dos genes HLA de classe II com a incapacidade de resposta humoral à vacina VHB.

Estudo de associação entre antígenos leucocitários humanos e doença de Jorge Lobo

A doença de Jorge Lobo é uma micose cutânea/subcutânea de evolução crônica, causada pelo fungo Lacazia loboi. Devido às características epidemiológicas e poucos estudos relacionados aos aspectos imunológicos dessa doença, o objetivo do trabalho foi investigar uma possível associação das especificidades HLA de classe II em 21 pacientes portadores da doença de Jorge Lobo, comparando com indivíduos sadios de mesma etnia. As tipificações HLA foram realizadas pelo método de PCR-SSP. O resultado não revelou qualquer tipo de associação entre os antígenos HLA e doença de Jorge Lobo. Embora sem significância estatística, foi observada a diminuição da freqüência do antígeno HLA-DR7 no grupo dos pacientes em relação aos controles (0% x 18%), sugerindo uma associação negativa (protetora) entre HLA-DR7 e doença de Jorge Lobo. Contudo, estudos devem ser continuados, objetivando melhor entendimento nos mecanismos envolvidos na suscetibilidade e/ou proteção dessa doença.

Avaliação do desempenho de parâmetros imunológicos como indicadores de progressão clínica da infecção crônica pelo HTLV-1

Neste estudo, foi avaliado o desempenho isolado e combinado de parâmetros laboratoriais, percentual de linfócitos B (%LB), a razão entre células T/B e o %CD8+HLA-DR+/CD8+, na identificação de indivíduos assintomáticos-AS ou portadores de HAM/TSP-HT numa população de casos soropositivos para HTLV-1. Índices expressos em porcentagem demonstram que cada parâmetro, isoladamente, apresenta desempenho moderado, com co-negatividade=83% e 91% para %LB e razão entre células T/B, respectivamente e co-positividade=78% para %CD8+HLA-DR+/CD8+. A análise combinada (%CD8+HLA-DR+/CD8+ e razão T/B) não revelou ganho significativo no desempenho (co-positividade=75%, co-negatividade=74%). A análise das razões de verossimilhança em diferentes faixas de valores, para os parâmetros isolados, revelou que um indivíduo soropositivo para HTLV-1 com %LB<7%, razão entre células T/B>11 e %CD8+HLA-DR+/CD8+>70% possui, respectivamente, 11, 19 e quase 10 vezes mais chances de pertencer ao grupo HT. Portanto, recomenda-se o uso desses indicadores fenótipos na propedêutica laboratorial complementar de monitoração da progressão clínica da infecção crônica pelo HTLV-1.

Estudo comparativo entre reação de Mitsuda e antígenos leucocitários humanos em pacientes hansenianos

Neste estudo, propomos comparar o teste cutâneo de Mitsuda e os alelos HLA-DR2/HLA-DR3 e HLA-DQ1 relacionados com as formas clínicas da hanseníase em 176 pacientes (50 TT, 50 LL e 76 B). Os resultados obtidos não revelaram associação entre reação de Mitsuda e os alelos HLA nas formas clínicas isoladas; no entanto, quando analisados de acordo com a resposta ao teste de Mitsuda, associação significativa foi encontrada entre os pacientes Mitsuda negativos e HLA-DQ1 (p=0,002). Não foi observada associação entre reação de Mitsuda positiva e alelos HLA-DR2/DR3. Concluímos que existe importante participação do alelo HLA-DQ1 na ausência de resposta ao teste de Mitsuda. Sugerimos estudos mais específicos para este alelo.

Extração de DNA a partir de sangue humano coagulado para aplicação nas técnicas de genotipagem de antígenos leucocitários humanos e de receptores semelhantes à imunoglobulina

O objetivo deste estudo foi padronizar uma metodologia de extração de DNA de alta qualidade a partir de amostras de sangue coagulado. Quarenta e oito amostras de sangue humano coagulado foram utilizadas para a extração de DNA pelo kit comercial EZ-DNA® (Biological Industries, Beit Haemek, Israel), pelo kit de coluna Neoscience® (One Lambda Inc., San Diego, CA) e pelo método modificado de salting out. Apenas o método de salting out foi capaz de extrair altas concentrações de DNA (média, 180ng/µL), as quais foram medidas pelo detector de fluorescência Qubit® (Invitrogen, USA). Este método permitiu a amplificação dos genes HLA (human leukocyte antigens) pela tecnologia PCR-SSO (polymerase chain reaction - specific sequence of oligonucleotides) Luminex, a qual exige DNA de boa qualidade, e de genes KIR (killer cell immunoglobulin-like receptors) pela técnica made in house PCR-SSP (polymerase chain reaction-sequence specific of primers), a qual demanda uma concentração específica de DNA (10ng/µL). Concluímos que a técnica de salting out modificada foi muito eficiente, simples e rápida para a extração de DNA de amostras de sangue humano coagulado, com o objetivo de realizar a genotipagem de genes HLA e KIR.

Class-I human leukocyte alleles in leprosy patients from Southern Brazil

INTRODUCTION: The present study was designed to investigate a possible role of HLA (histocompatibility leucocyte antigen) class-I alleles (HLA-A, -B, and -C) in leprosy patients from Southern Brazil. METHODS: Two hundred and twenty-five patients with leprosy and 450 individuals for the control group were involved in this research. HLA genotyping was performed through PCR-SSO protocols (One Lambda, USA); the frequency of these alleles was calculated in each group by direct counting, and the frequencies were then compared. RESULTS: There was an association between HLA-A*11 (6.9% vs 4.1%, p=0.0345, OR=1.72, 95% CI=1.05-2.81), HLA-B*38 (2.7% vs. 1.1%, p=0.0402, OR=2.44, 95% CI=1.05-5.69), HLA-C*12 (9.4% vs. 5.4%, p=0.01, OR=1.82, 95% CI=1.17-2.82), and HLA-C*16 (3.1% vs. 6.5%, p=0.0124, OR=0.47, 95% CI=0.26-0.85) and leprosy per se. In addition, HLA-B*35, HLA-C*04, and HLA-C*07 frequencies were different between lepromatous (LL) and tuberculoid (TT) patients. However, after adjusting for the number of alleles compared, Pc values became nonsignificant. CONCLUSIONS: Although our results do not support the previous findings that HLA class-I alleles play a role in leprosy pathogenesis, we suggest new studies because of the importance of the association between the HLA and KIR in the innate immune response to leprosy.

S100, CD68, and MHC class II molecule expression in cervical high- and low-grade HPV-induced lesions

INTRODUCTION: Some human papillomavirus (HPV) types are involved in malignant processes in the cervical epithelium, with 99% of cases attributed to oncogenic HPV infection. This study aimed to detect S100, CD68, and major histocompatibility complex class II (MHC-II) molecules in cervical uterine epithelial samples in patients with high- and low-grade lesions induced by HPV. METHODS: Fifty-eight samples from patients who were confirmed positive or negative for high-risk oncogenic HPV DNA, had histopathological diagnosis of cervical intraepithelial neoplasia (CIN) of grades I, II, or III, or were negative for intraepithelial lesion or malignancy were subjected to immunohistochemistry reaction to S100 protein, CD68, and MHC-II (HLA-DR alpha chain). RESULTS: The presence of MHC-II predominated in samples exhibiting histopathological alterations (p < 0.05). S100 detection was more numerous in carcinoma samples (CIN III) (75%). Presence of this protein correlated significantly (p < 0.05) with histopathological findings and viral load. CONCLUSIONS: A small expression of CD68 was observed, which may be explained by the observation in our study having been made on random microscopic fields and not on specific areas. The findings, such as the presence of S100 protein and MHC-II expression in samples with histological alterations, could suggest that the immune system fails to control HPV replication at the early stages of infection. Further studies with larger prospective data are necessary to confirm this result.

Understanding how dentritic cell glycans affect antitumor immune responses

RESUMO: As células dendríticas (DCs) têm a capacidade única de induzir respostas imunitárias contra as células tumorais, fagocitando antigénios tumorais e apresentando-os às células T, provocando respostas imunitárias específicas que conduzem à eliminação de células de tumorais. Por induzirem memória imunológica de longa duração, as DCs são uma estratégia atrativa para o tratamento e/ou prevenção do cancro. No entanto, os resultados terapêuticos obtidos em ensaios clínicos com DCs são escassos e pouco eficientes. O nosso grupo demonstrou que ácidos siálicos que contêm glicanos desempenham um papel funcional importante em DCs geradas ex vivo. Com o objetivo de estabelecer um modelo in vitro para avaliar a resposta anti-tumoral específica realizou-se um tratamento enzimático a DCs derivadas de monócitos (moDCs) com sialidase, enzima que cliva ácidos siálicos na superfície celular. O perfil de maturação de moDCs foi caracterizado por citometria de fluxo e expressão de citocinas. Os resultados mostram que a sialidase pode regular positivamente a expressão de moléculas co-estimuladoras na superfície de moDCs estimuladas com agonistas de Toll like receptors (TLRs). Para percebermos se o tratamento com sialidase afeta a sinalização dos TLRs foram usadas células HEK transfectadas de forma estável com TLRs 2, 4 and 7/8. Os dados mostraram que a desialilação não afeta a sinalização através estes recetores. Para investigar o impacto funcional da sialidase na capacidade de moDCs em apresentar um antigénio e ativar células T, moDCs foram tratadas, ou não, com sialidase e cultivadas com clones de células T CD8+ específicas para os péptidos derivados do antigénio tumoral gp100. Os resultados mostram que DCs HLA*02:01+ desialiladas exibem maior cross-presentation do péptido gp100280-288 às células T CD8+ específicas. Além disso o tratamento com sialidase também aumenta a capacidade de DCs de induzir a proliferação de células T CD4+. Em conjunto, os resultados indicam que moDCs com menos ácidos siálicos na superfície, têm melhor potencial imuno-estimulador, com maior capacidade de induzir respostas imunes anti-tumorais.--------------------- ABSTRACT: Dendritic cells (DCs) have a unique capacity to induce immune responses against tumor cells. They can phagocyte tumor antigens, maturate and present them to T cells, triggering antigen-specific immune responses that may lead to the elimination of tumor cells. Since they induce long-lasting immunological memory, DCs become an attractive strategy as cellular targets for vaccines in the treatment and/or prevention of cancer. However, the therapeutic results obtained in clinical trials with DCs are scarce and only few patients effectively respond to the DC vaccines. Our group has shown that sialic acid containing glycans play an important functional role in ex vivo generated DC. Here we aimed to establish an in vitro model to assess specific antitumor responses. To achieve this, an enzymatic treatment of monocyte-derived DCs (moDCs) was performed using sialidase to cleave surface sialic acids. The maturation profile of the moDCs was characterized by flow cytometry and cytokine expression. The results show that sialidase treatment can upregulate co-stimulatory molecules on surface of moDCs stimulated with Toll like receptor (TLR) agonists. To understand whether sialidase treatment affected the TLR signaling, we have used HEK cells stably transfected with TLRs 2, 4 and 7/8. The data showed that desialylation of moDCs does not affect the signaling via these receptors. To investigate the functional impact of sialidase treatment in the capacity of moDCs to present antigen and to activate antigen specific T cells, sialidase treated and untreated moDCs were co-cultured with CD8+ T cell clones specific for peptides derived from the gp100 tumor antigen. Our results show that desialylated HLA02:01+ DCs are superior in cross-presentation of the peptide to gp100280–288 specific CD8+ T cells. In addition, sialidase treatment also increased the DC capacity to induce CD4+ T cells proliferation. Together, these data indicate that moDCs with altered cell surface sialic acids, through a sialidase treatment, have a better immunostimulatory potential which could improve anti-tumor immune responses.

Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil

BACKGROUND: Diffuse panbronchiolitis is a clinical pathologic condition characterized by chronic inflammation of respiratory bronchioles, with clinical features that position it as a differential diagnosis among the sinopulmonary syndromes. METHODS AND RESULTS: We present 4 cases (1 Black, 2 Japanese descendants, and 1 Japanese), living in Brazil, in which the diagnosis was made by the clinical and radiological features and confirmed by transbronchial biopsy. The clinical findings included chronic sinusitis, productive cough, rhonchi, and wheezes. The pulmonary function tests showed an obstructive pattern. High resolution computerized tomography showed a diffuse nodular pattern, airway ectasia, and airway wall thickening. The biopsy showed interstitial accumulation of foam cells and lymphoid cells in the walls of respiratory bronchioles: 2 of our cases had bronchus-associated lymphoid tissue hyperplasia. We searched for the HLA Bw54 in all of our patients, but only 1 was positive. A low dose macrolide treatment was introduced, resulting in with clinical and functional improvement. A score that rated the extent of nodules, airway ectasia, mucus plugging, and airway wall thickening was applied on pre- and post-treatment High resolution computerized tomography results, revealing an improvement in tomographic pattern related to that observed in the pulmonary function tests. CONCLUSION: We conclude that diffuse panbronchiolitis is a systemic disease that is not exclusive to the Asian population, whose clinical and radiological features should be better known by occidental pulmonary physicians.

Infección de macrófagos con el Virus Encefalitis Saint Louis: efecto sobre el fenotipo celular y la apoptosis.

El virus Encefalitis Saint Louis (VESL) (género Flavivirus) experimenta una re-emergencia en la región central del país, con la ocurrencia de un brote en Córdoba y el aislamiento de cepas de distintos genotipos. Está demostrado que los Flavivirus neurotrópicos, como VESL, replican en macrófagos y células dendríticas, tanto en el tejido local como en nódulos linfáticos satélites, para luego llegar a torrente sanguíneo y ser transportados a sistema nervioso central. Es así que el nivel de viremia inicial es regulado por la depuración del virus que realizan los macrófagos. Estas células reconocen a los virus por medio de receptores de reconocimiento de patrones moleculares asociados a patógenos, que incluyen a los receptores Toll-like (TLR). La relación entre los TLR y los virus, se fundamenta en tres aspectos: 1) los TLR al ser estimulados por moléculas derivadas de virus activan vías de señalización que inducen la producción de citoquinas pro-inflamatorias, como TNF- , IL-1, 6, 8 y 18, INF-  y , que median la respuesta inmune antiviral; 2) las señales que dependen de los TLR median efectos inmunopatogénicos, como la apoptosis y la patogénesis del virus; 3) algunas estrategias terapéuticas o profilácticas antivirales se basan en la estimulación de los TLR mediante los respectivos agonistas. Como parte de la respuesta del macrófago a la infección viral, hay proliferación, diferenciación y muerte celular. A la hora de morir, estas células pueden seguir el camino que lleva a la necrosis o el de la apoptosis. Durante la activación de la respuesta inmune frente a antígenos extraños, la apoptosis es requerida para eliminar las células efectoras, una vez que han ejecutado su función y así evitar el desarrollo de procesos deletéreos para el huésped. Estudios realizados con distintos Flavivirus documentan el incremento de apoptosis de macrófagos durante la progresión de la infección y también su relación con la severidad de la patología. De acuerdo a los antecedentes expuestos, se formulan las siguientes hipótesis de estudio: 1-El fenotipo de activación del macrófago infectado con VESL está relacionado con el genotipo viral. 2-La clase de inmunomoduladores liberados y el grado de apoptosis de los macrófagos infectados con el VESL dependen del receptor de reconocimiento utilizado por el virus.El objetivo principal es caracterizar la respuesta inmune inducida en macrófagos infectados in vitro con diferentes genotipos de VESL. Para ello se plantean los siguientes objetivos específicos: 1-Determinar la capacidad de replicación de VESL en macrófagos.2-Evaluar la expresión de molécula de superficie, receptores y la producción de inmunomoduladores en macrófagos infectados con VESL.3-Analizar el impacto de la infección con VESL sobre la apoptosis de macrófagos.4-Correlacionar la expresión de antígenos de superficie, receptores, producción de inmunomoduladores, apoptosis y carga viral con el genotipo viral que infecta al macrófago.Se utilizará una línea línea celular mieloide U937 y cepas del VESL genotipo III, V y VII. Se estudiará la infección de las mismas y determinará la expresión de: CD14, CD16, CD54/ICAM-1, HLA-DR, Fas, R-TNF, CD86, IL4R, TLR2, TLR3, TLR4 y TLR7 por Citometría de Flujo. En el sobrenadante de los cultivos infectados se cuantificarán las concentraciones de IFN-, IFN-, TNF-, IL-1, IL-6, IL-8, IL-10, IL-12, IL-18 y TGF- por técnica de ELISA.Se determinará la apoptosis en los macrófagos infectados mediante marcación con Anexina V-Ficoeritrina y análisis de fragmentación del ADN.La emergencia de esta virosis en nuestro medio amerita abordar distintos aspectos de la respuesta inmune en esta infección. El conocimiento de las características de la activación del macrófago cuando se infecta con VESL, los inmunomoduladores liberados y el impacto de la infección sobre la apoptosis de ésta célula, aportaría posibles blancos para el diseño futuro de estrategias terapéuticas o profilácticas contra esta infección.

Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.

HLA-A2+ melanoma patients develop naturally a strong CD8+ T cell response to a self-peptide derived from Melan-A. Here, we have used HLA-A2/peptide tetramers to isolate Melan-A-specific T cells from tumor-infiltrated lymph nodes of two HLA-A2+ melanoma patients and analyzed their TCR beta chain V segment and complementarity determining region 3 length and sequence. We found a broad diversity in Melan-A-specific immune T-cell receptor (TCR) repertoires in terms of both TCR beta chain variable gene segment usage and clonal composition. In addition, immune TCR repertoires selected in the patients were not overlapping. In contrast to previously characterized CD8+ T-cell responses to viral infections, this study provides evidence against usage of highly restricted TCR repertoire in the natural response to a self-differentiation tumor antigen.

Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Retroviral transfer of T cell antigen receptor (TCR) genes selected by circumventing tolerance to broad tumor- and leukemia-associated antigens in human leukocyte antigen (HLA)-A*0201 (A2.1) transgenic (Tg) mice allows the therapeutic reprogramming of human T lymphocytes. Using a human CD8 x A2.1/Kb mouse derived TCR specific for natural peptide-A2.1 (pA2.1) complexes comprising residues 81-88 of the human homolog of the murine double-minute 2 oncoprotein, MDM2(81-88), we found that the heterodimeric CD8 alpha beta coreceptor, but not normally expressed homodimeric CD8 alpha alpha, is required for tetramer binding and functional redirection of TCR- transduced human T cells. CD8+T cells that received a humanized derivative of the MDM2 TCR bound pA2.1 tetramers only in the presence of an anti-human-CD8 anti-body and required more peptide than wild-type (WT) MDM2 TCR+T cells to mount equivalent cytotoxicity. They were, however, sufficiently effective in recognizing malignant targets including fresh leukemia cells. Most efficient expression of transduced TCR in human T lymphocytes was governed by mouse as compared to human constant (C) alphabeta domains, as demonstrated with partially humanized and murinized TCR of primary mouse and human origin, respectively. We further observed a reciprocal relationship between the level of Tg WT mouse relative to natural human TCR expression, resulting in T cells with decreased normal human cell surface TCR. In contrast, natural human TCR display remained unaffected after delivery of the humanized MDM2 TCR. These results provide important insights into the molecular basis of TCR gene therapy of malignant disease.

Prevention of bone marrow graft failure by an anti LFA-1 monoclonal antibody

Graft rejection is the major cause of failure of HLA mismatched bone marrow transplantation because of residual host immunity. we have proposed to use a monoclonal murine antibody specific for the LFA-1 molecule (25-3) to prevent graft failure in HLA mismatched bone marrow transplantation (BMT). The rationale for this approach is three fold: LFA-1 deficient patients (3/3) do not reject HLA mismatched BMT; anti LFA-1 blocka in vitro the induction of T cell responses and T/ non T cytotoxic functions; LFA-1 is not expressed by other cells than leucocytes. We have accordingly treated twenty two patients with inherited diseases and 8 with leikemia. The bone marrow was T cells depled by E rosetting of Campath antibody. The antibody was given at days -3, -1, +1, +3, +5 at dose of .1 mg/kg/d for the first 9 and then .2mg/kg/d from day -3 to +6. Engraftment occured in 23/30 patients as shown by at least HLA typing. Hematological recovery was rapid, GVH was limited. Side effects of antibody infusion included fever and possibly an increased incidence of early bacteral infection (sepsis, 1 death). Immunological reconstitution occured slowly leading in six cases to EBV-induced B cell poliferation (1 death and in two others to transient auto immune hemolytic anemia. There has been only one secondary graft rejection. Sisteen patients are alive 3 to 26 months post transplant with functional grafts. Although the number of patients treated is still low the absence of late rejection so far, gives hope for long term maintenance of the graft using anti LFA-1. Since the antibody is an IgG 1 unable to bind human complement, and since it is known to inhibit phagocytosis, there is a good suggestion that 25-3 act through functional blocking of host T and non T luymphocytes at both induction and effector levels.